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ABSTRACT
Background. A phase III trial compared lapatinib plus
letrozole (L  Let) with letrozole plus placebo (Let) as
first-line therapy for hormone receptor (HR)
 meta-
static breast cancer (MBC) patients. The primary end-
point of progression-free survival (PFS) in patients
whose tumors were human epidermal growth factor re-
ceptor (HER)-2
 was significantly longer for L  Let
than for Let (8.2 months versus 3 months; p  .019).
This analysis focuses on quality of life (QOL) in the
HER-2
 population.
Methods. QOL was assessed at screening, every 12
weeks, and at withdrawal using the Functional Assess-
ment of Cancer Therapy–Breast (FACT–B). Changes
from baseline were analyzed and the proportions of pa-
tients achieving minimally important differences in
QOL scores were compared. Additional exploratory
analyses evaluated how QOL changes reflected tumor
progression status.
Results. Among the 1,286 patients randomized, 219
hadHER-2
tumors.BaselineQOLscoreswerecompa-
rable in the two arms. Mean changes in QOL scores
were generally stable over time for patients who stayed
on study. The average change from baseline on the
FACT-B total score in both arms was positive at all
scheduled visits through week 48. There was no signifi-
cant difference between the two treatment arms in the
percentage of QOL responders.
Conclusion. The addition of lapatinib to letrozole led
to a significantly longer PFS interval while maintaining
QOL during treatment, when compared with letrozole
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The Oncologist 2010;15:944–953 www.TheOncologist.comalone, thus confirming the clinical benefit of the combi-
nation therapy in the HR
 HER-2
 MBC patient pop-
ulation. This all oral regimen provides an effective
option in this patient population, delaying the need for
chemotherapy and its accompanying side effects. The
Oncologist 2010;15:944–953
INTRODUCTION
Breast cancer continues to remain one of the most fre-
quently diagnosed cancers and is among the leading causes
of cancer death among women across the globe. In 2009,
192,370womenintheU.S.wereestimatedtohavereceived
a diagnosis of breast cancer and 40,170 women were ex-
pected to die from the disease [1]. Approximately 70% of
breast cancers are estrogen dependent (hormone receptor
[HR]sensitive),andthemajority(65%)ofnewlydiagnosed
patients are postmenopausal (55 years of age) with a me-
dian age at diagnosis of 60 years.
Despite recent advances in the treatment of HR
 meta-
static breast cancer (MBC) patients using endocrine thera-
pies (third-generation aromatase inhibitors, such as
letrozole, anastrozole, or exemestane), resistance to these
therapies limits their success. There is evidence to suggest
that crosstalk between pathways involving the epidermal
growth factor family of receptors—epidermal growth fac-
torreceptor(EGFR)andhumanepidermalgrowthfactorre-
ceptor 2 (HER-2)—and the estrogen receptor (ER) may be
a contributing factor to resistance to endocrine therapy
[2–6]. This has supported a rationale for using targeted
agents against EGFR pathways in combination with endo-
crine manipulation to overcome endocrine resistance. In a
recent randomized, open-label trial for the first-line treat-
ment of postmenopausal women with HR
 HER-2
 MBC,
trastuzumab combined with anastrozole doubled the me-
dian progression-free survival (PFS) time, compared with
anastrozole alone, 2.4 months versus 4.8 months [7]. This
combination trastuzumab–aromatase inhibitor regimen is
approved in the European Union but has not yet been ap-
proved in the U.S.
Because HER-2 overexpression is a poor prognostic
factor and HER-2
 MBC is a rapidly progressive disease,
the use of anti–HER-2 therapy in combination with chemo-
therapy,ratherthanincombinationwithantihormonalther-
apy, is common in clinical practice. For patients with
HER-2
 tumors, chemotherapy is unlikely to be used with-
out an anti–HER-2 agent. Trastuzumab in combination
with taxanes is the standard of care in this front-line MBC
setting regardless of HR status. Although studies have in-
dicatedalongertimetotumorprogressionwiththeaddition
oftrastuzumabtochemotherapy-basedregimensinpatients
with HER-2
 MBC [8, 9], treating incurable patients with
palliative front-line chemotherapy may be considered
overly aggressive in this setting and may unnecessarily ex-
pose patients to serious toxicities associated with chemo-
therapy (including neutropenia, leukopenia, neuropathy,
asthenia, myalgia, and arthralgia). Moreover, as a patient’s
diseaseprogresses,theyoftenexperiencepainfulanddebil-
itating metastases to the brain, bones, and other organs,
which when combined with treatment toxicities can signif-
icantly impact quality of life (QOL) [10–13]. Hence, the
clinical benefit of therapy for MBC patients must be
weighedagainstitspotentialnegativeimpactontheQOLof
these women.
Lapatinib, a potent, orally active, dual tyrosine kinase
inhibitorofEGFRandHER-2iscurrentlyapprovedforuse
in combination with capecitabine for the treatment of ad-
vanced or metastatic HER-2
 breast cancer in women pre-
viously treated with other anticancer drugs. A recent large,
randomized, double-blind phase III trial (EGF30008)
showed the combination of lapatinib with the aromatase in-
hibitor letrozole to delay progression significantly longer
(8.2 months versus 3 months; hazard ratio, 0.71; 95% con-
fidence interval, 0.53–0.96; p  .019) than with letrozole
aloneinpatientswithknownHR
HER-2
MBCreceiving
first-line treatment [14]. This paper presents analyses eval-
uating QOL in patients with HR
 HER-2
 tumors receiv-
ing letrozole alone or in combination with lapatinib in
clinical trial EGF30008.
METHODS
Study Design and Patient Population
The EGF30008 study was a phase III, randomized, double-
blinded, placebo-controlled, parallel-group, and multi-
center trial. Eligible patients were postmenopausal women
with histologically confirmed stage IIIB/IIIC or IV ER

and/or progesterone receptor–positive invasive breast can-
cerwhohadnotreceivedpriortherapyforadvancedormet-
astatic disease. Details of the patient population for clinical
trial EGF30008 have been previously described [14]. The
protocol was approved by institutional review boards, and
informed consent was obtained from all patients. Patients
were randomly assigned to receive either: (a) lapatinib,
1,500 mg/day, plus letrozole, 2.5 mg/day, or (b) letrozole,
2.5 mg/day, with matching placebo. Patients were treated
daily until disease progression or withdrawal from study as
a result of unacceptable toxicity or other reasons. The pri-
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pare PFS in patients with HER-2
 tumors. Secondary
objectives included the overall response rate, the clinical
benefit rate, the overall survival time, safety, and the PFS
interval for the intent-to-treat (ITT) population. Assessing
the impact of study treatments on QOL in the HER-2
 and
ITTpopulationswasoneofthesecondaryobjectivesofthis
trial. The QOL analysis presented here uses clinical data as
of the cutoff date of June 3, 2008.
QOL Instrument
QOL was assessed on day 1, every 12 weeks, and at study
withdrawal using the Functional Assessment of Cancer
Therapy–Breast (FACT-B) questionnaire (version 4,
1997). The FACT-B consists of the FACT–General
(FACT-G) plus breast cancer subscale (BCS), which com-
plements the general scale with items specific to QOL in
breast cancer. The FACT-B is designed to measure multi-
dimensional QOL in patients with breast cancer [15]. It is a
37-item(27generalquestionsand10breastcancer–specific
questions) self-reporting instrument consisting of five di-
mensions/subscales: physical well-being (PWB), social/
family well-being (SWB), emotional well-being (EWB),
functional well-being (FWB), and the BCS. Patients as-
sessed how true each statement had been for them in the
previous 7 days on a five-point scale (0, not at all; 1, a little
bit; 2, somewhat; 3, quite a bit; 4, very much). The PWB,
SWB, and FWB subscales each have seven questions,
whereas the EWB subscale has six questions. The BCS has
10breastcancer–relatedquestionsandmainlyaskspatients
to report how much they may have been bothered by vari-
oussymptomsincludingshortnessofbreath,hairloss,pain,
and weight change. The five subscale scores are used to de-
rive three assessment outcomes—the FACT-B total score,
FACT-G score, and trial outcome index (TOI).
The FACT-B total score is calculated by summing all
five unweighted subscale scores, with total scores in the
range of 0–136. The FACT-G score is calculated by sum-
ming four of the five unweighted subscale scores, specifi-
cally the PWB, SWB, EWB, and FWB scores (i.e.,
excluding the BCS), with scores in the range of 0–108. The
TOI, an efficient summary index of physical/functional
outcomes, is the sum of the PWB, FWB, and BCS scores,
with scores in the range of 0–84. As per FACT-B scoring
guidelines, these three scores were calculated only when
patients responded to at least 80% of the items that consti-
tuted the relevant score.
Inapreviousstudy,whichconsideredbothdistribution-
and anchor-based estimates, a minimally important differ-
ence (MID) was estimated to be 2–3 points for the BCS,
7–8 points for the FACT-B total score, and 5–6 points for
the FACT-G and the TOI scores [16].
Statistical Analysis
Patients had to have completed the baseline FACT-B ques-
tionnaire and at least one follow-up questionnaire to be in-
cluded in analyses. Changes from baseline in the FACT-B
totalscore,FACT-Gscore,andTOIscoreateachscheduled
visit and at withdrawal were analyzed by parametric anal-
ysisofcovariance(ANCOVA)usingthebaselinescoreasa
covariate. Because the duration of follow-up varied across
patients, the analyses were repeated using the last observa-
tion carried forward (LOCF) approach to account for miss-
ing scores. In this approach, missing FACT-B scores from
scheduled visits were imputed from the last nonmissing
score at a previous visit. Results from the ITT population
were considered as secondary analyses, because the
HER-2
 population was identified a priori as the primary
population for analysis.
A QOL responder analysis was also performed. A pa-
tient was classified as a QOL responder or nonresponder
based on whether the patient achieved a MID on the rele-
vantQOLscore[16].AMIDwasdefinedastheupperlimit
of the published differences for the FACT-B total,
FACT-G, and TOI scores (eight points for the FACT-B to-
tal score and six points for the FACT-G and TOI scores).
The best QOL response during follow-up (including sched-
uled and withdrawal visits) was used to determine response
status. In a sensitivity analysis, an alternative definition of
QOL responders, which used the lower limit of the pub-
lished MIDs instead of the upper limit (seven points for the
FACT-B total score and five points for the FACT-G and
TOI scores), was employed.
In a post hoc exploratory analysis in the HER-2
 pop-
ulation, the extent to which QOL scores reflected tumor
progression events was assessed by examining QOL
changes at consecutive time points by progression status.
At weeks 12, 24, and 36, QOL scores were pooled across
treatment arms and stratified based on investigator assess-
mentofprogressionpriortoorupto1weekafterthesched-
uled assessment. For those patients who had not progressed
by week 12, QOL scores were again examined at week 24,
stratifiedbywhetherthepatienthadprogressedornotinthe
interim. This approach was continued through week 36, af-
ter which too few patients with QOL data remained on
study. The QOL score change from baseline was compared
between progressors and nonprogressors using the least
squared means from an ANCOVA, adjusted for baseline
value. The distribution of QOL responses stratified by
whether the change from baseline represented minimally
946 Quality of Life in MBC Patientsimportantdeclines,increases,orstabilitywascomparedus-
ing Fisher’s exact test.
RESULTS
Patient Characteristics and QOL Completion
Rates
Between December 9, 2003 and December 29, 2006, 1,286
patients in total were randomly assigned to treatment, of
whom17%(219patients)hadcentrallyconfirmedHER-2

tumors (n  111 for the lapatinib plus letrozole arm, n 
108 for the letrozole plus placebo arm). Baseline patient
and disease characteristics were well balanced between
treatment arms for both the HER-2
 and ITT HR
 popula-
tions and have been previously reported [14].
ThenumberofHER-2
patientswithscorableFACT-B
assessments at scheduled and concluding/withdrawal visits
is provided in Table 1; percentages are shown based on pa-
tientswhowerestillonstudy(i.e.,excludingthosewhohad
progressed, were censored for progression, or withdrew
from treatment and hence were not required to complete
the assessments at future visits). QOL questionnaire
completion rates over the first year of follow up were
93%–100% of the available patients for both treatment
arms, with the exception of the letrozole arm at week 48,
which was 85%.
Change in QOL from Baseline
Baseline QOL scores (FACT-B subscales and total,
FACT-G, TOI) were generally comparable in the two arms
(Table 2). Because QOL assessments were stopped after
treatment termination or disease progression, few patients
completed the questionnaire after week 48, and the results
reported here are only for the visits up to week 48.
In general, average scores on the FACT-B, FACT-G,
and TOI were unchanged during the first year of treatment
(Fig. 1). In both treatment arms, small positive average
changes in total FACT-B scores were observed during
treatment, which did not reach MID levels until late in year
2 or 3 when few patients remained on study. As expected,
average FACT-B scores at the concluding (progression or
study withdrawal) visit represented minimally important
decreases in QOL for both treatment arms (lapatinib plus
letrozole, 8.9; letrozole plus placebo, 9.5). The same
Table 1. Number of HER-2
 patients completing the Functional Assessment of Cancer Therapy–Breast questionnaire at
scheduled visits
Visit n available
Lapatinib  letrozole
(n  111) n available
Letrozole  placebo
(n  108)
Day 1, baseline 110 110 (100%) 103 101 (98%)
Wk 12 88 87 (99%) 68 65 (96%)
Wk 24 64 63 (98%) 40 39 (98%)
Wk 36 42 40 (95%) 27 25 (93%)
Wk 48 32 31 (97%) 27 23 (85%)
Wk 60 23 21 (91%) 19 15 (79%)
Wk 72 19 18 (95%) 19 17 (90%)
Wk 84 13 12 (92%) 14 13 (93%)
Wk 96 11 11 (100%) 11 10 (91%)
Wk 108 8 7 (88%) 7 6 (86%)
Wk 120 7 6 (86%) 6 5 (83%)
Wk 132 4 4 (100%) 5 2 (40%)
Wk 144 3 2 (67%) 4 2 (50%)
Wk 156 1 1 (100%) 2 2 (100%)
Wk 168 1 1 (100%) 2 2 (100%)
Wk 180 1 1 (100%) 1 0 (0.0%)
Conclusion/withdrawal 110 78 (71%) 103 67 (65%)
Complete was defined as completing at least one question in the quality-of-life questionnaire among those who completed a
baseline questionnaire.
Percentage is of those who were scheduled to complete a questionnaire at the visit time (i.e., not progressed, censored for
progression, or withdrawn from treatment).
Abbreviation: HER-2, human epidermal growth factor receptor 2.
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magnitude of decline similar across treatment arms. None
of the differences between groups were statistically signif-
icant. For the five dimensions/subscales, changes from
baseline were small in both treatment arms. From week 12
to week 48, small differences were observed between the
two arms at each follow-up, relative to baseline (Table 3).
Most of the differences were not statistically significant
(except for two subscales at the week 12 visit: a 1.5-point
differenceintheBCSinfavorofthecombinationanda1.5-
point difference in the SWB subscale in favor of letrozole
alone), and the differences did not reach MID levels.
Results for the FACT-B and FACT-G using the LOCF
approach on the HER-2
 population were consistent with
observed data. For the TOI, a small positive increase at
week 12 favored the lapatinib plus letrozole group (p 
.03). Differences in declining TOI scores very late in the
study also favored the combination group (.05  p  .10
after week 144), but these differences were small and not
MIDs. In the ITT population, statistically significant
FACT-B, FACT-G, and TOI scores favored the letrozole
plus placebo arm over the lapatinib plus letrozole arm at
weeks12,24,and36,intherangeof3.2to1.6,butnone
ofthesecouldbeconsideredMIDs.AsintheHER-2
anal-
ysis, average scores in both arms were higher than baseline
during the first year of treatment, except for study with-
drawal assessments.
More than one third (34%–41%) of HER-2
 patients
wereidentifiedasQOLrespondersduringthetreatmentpe-
riod (Table 4). The proportions of patients achieving MID
improvements on the FACT-B, FACT-G, and TOI were
equal between the two treatment groups or slightly favored
the combination arm; none of the differences was statisti-
cally significant. Similar results were obtained using the
lower limit of the published MIDs as a sensitivity analysis.
Relationship Between QOL and Tumor Response
Betweenrandomizationandtheweek12visit(includingup
to 1 week beyond the scheduled assessment), 72 HER-2

patients experienced disease progression events (including
one death) and 144 patients had tumors that did not meet
progressioncriteria.Ofthese144,10werecensored,37ex-
perienced disease progression (including one death) by the
week 24 visit, and 97 still did not have disease progression
at week 24. By the time of the week 36 visit, another seven
patients were censored, 21 had tumors with disease pro-
gression (including one death), and 69 remained progres-
sion free.
For patients who stayed on treatment and did not
progress over a 36-week period, changes from baseline in
FACT-B total scores remained stable and within MID lev-
els (represented by the highlighted area in Figure 2). Aver-
age QOL declines reached clinically and statistically
significant levels for patients whose tumors progressed af-
ter week 12, but not for patients whose tumors progressed
earlier. Differences in average changes from baseline in
FACT-Btotalscoreswerestatisticallyandclinicallysignif-
icant between patients who experienced progression events
and those who did not at week 24 (p  .0001) and week 36
(p  0.04) but not at week 12 (p  .16).
At week 12, the distribution of patients by FACT-B re-
sponse level was similar between patients whose disease
progressed and those whose disease did not progress (p 
Table 2. Summary of baseline FACT-B subscale, FACT-B total, FACT-G, and TOI scores by treatment arm, HER-2

population
Lapatinib  letrozole
(n  111)
Letrozole  placebo
(n  108)
Assessment (score range) n Mean (SD) n Mean (SD)
Physical well-being subscale (0–28) 106 21.8 (5.05) 99 21.2 (5.22)
Social/family well-being subscale (0–28) 109 20.9 (5.86) 98 22.4 (5.95)
Emotional well-being subscale (0–24) 110 15.6 (4.50) 100 16.0 (4.85)
Functional well-being subscale (0–28) 110 17.5 (5.68) 100 17.7 (5.93)
Breast cancer subscale (0–36) 108 23.2 (5.19) 98 23.6 (5.98)
FACT-B total (0–144) 104 99.3 (19.16) 96 101.1 (19.31)
FACT-G (0–108) 105 75.9 (15.65) 98 77.4 (15.64)
TOI (0–92) 103 62.5 (12.77) 97 62.4 (13.65)
Abbreviations: FACT-B, Functional Assessment of Cancer Therapy–Breast; FACT-G, Functional Assessment of Cancer
Therapy–General; HER-2, human epidermal growth factor receptor 2; SD, standard deviation; TOI, trial outcome index.
948 Quality of Life in MBC Patients.69) (Fig. 3). For patients with disease progression between
week 12 and week 24, 65% had FACT-B declines more
than seven points from baseline, versus 18% of patients
without disease progression (p  .0001). Results were sim-
ilar at week 36, but not statistically significant (p  .15).
The pattern of QOL changes and distribution of MID re-
sponse levels was consistent for the TOI and BCS scores
(data not shown).
Figure 1. Treatment group changes from baseline for FACT-B total, FACT-G, and TOI scores, HER-2 population. Least
squares mean changes (95% CI) from analysis of covariance, adjusted for baseline score. Bars indicate  1.96 standard error.
Abbreviations: CI, confidence interval; FACT-B, Functional Assessment of Cancer Therapy–Breast; FACT-G, Functional
Assessment of Cancer Therapy–General; HER-2, human epidermal growth factor receptor 2; L  Let, lapatinib  letrozole; Let,
letrozole; MID, minimum important difference; TOI, trial outcome index.
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In addition to clinical benefits such as delayed tumor pro-
gression, higher tumor response rates, and longer survival,
anothergoaloftreatingwomenwithMBCistoprovidepal-
liation and maintain or even improve their QOL. QOL was
measured in this study because it was important to investi-
gate whether additive therapy (lapatinib plus letrozole),
compared with letrozole alone, caused any detrimental ef-
fects on QOL in this patient population with metastatic dis-
ease. Results suggest that the addition of lapatinib to a
currently accepted regimen for HER-2
 MBC patients did
not deteriorate patient QOL.
Analyses of QOL scores and changes from baseline in
the HER-2
 and ITT populations in the EGF30008 trial
showedthatmeanchangesinsubscaleandtotalQOLscores
weregenerallystableovertimeinbothtreatmentgroupsfor
patientswhostayedontreatment.Thefactthatnostudydif-
ference in QOL was observed between treatment groups
was an expected finding. Current oncology study designs
make it difficult to evaluate the full magnitude of the effect
on QOL over time, because assessments are typically
stopped after withdrawal of the randomized treatment,
which usually coincides with progression. Although the
current study had high response rates on QOL assessments,
limited data were available postprogression because QOL
assessments were not required during that time, as per the
studyprotocol.Asaconsequence,fewpatients,particularly
in the placebo arm, had QOL data available over the entire
follow-up. Hence, any postprogression QOL benefit result-
ing from delaying progression with lapatinib and letrozole
treatment could not be evaluated. Thus, the QOL analysis
that was conducted based on available data was conserva-
tive and possibly biased against lapatinib, because postpro-
gression patients were missing from the placebo arm at a
higher rate. Even if data were available postprogression, it
is likely that these data would have been confounded by
subsequent treatments that the patients received.
In another study of women with HER-2
 MBC, who
had been previously treated and hence had higher disease
severity, the addition of lapatinib to capecitabine was
Table 3. Treatment group differences in Functional Assessment of Cancer Therapy–Breast subscales, HER-2
 population
Subscale Wk 12 Wk 24 Wk 36 Wk 48
Physical well-being 0.6 1.1 0.8 0.2
Social/family well-being 1.5
a 1.1 0.8 1.2
Emotional well-being 0.3 0.7 0.7 0.1
Functional well-being 0.2 0.2 0.7 2.0
Breast cancer subscale 1.5
a 1.0 0.1 0.9
Differences were adjusted for baseline score. Positive numbers favor the lapatinib plus letrozole treatment arm.
ap  .05.
Abbreviation: HER-2, human epidermal growth factor receptor 2.
Table 4. Treatment group comparison of quality of life responders during study, HER-2
 population
Quality of life score Lapatinib  letrozole Letrozole  placebo
p-value for treatment
difference
a
FACT-B total n  98
b n  85
b
8 (MID upper bound) 33 (34%) 29 (34%) .99
7 (MID lower bound) 36 (37%) 29 (34%) .758
FACT-G n  99 n  87
6 (MID upper bound) 38 (38%) 29 (33%) .54
5 (MID lower bound) 41 (41%) 34 (39%) .766
Trial outcome index n  97
b n  87
b
6 (MID upper bound) 33 (34%) 29 (33%) .99
5 (MID lower bound) 36 (37%) 30 (34%) .759
ap-values are from Fisher’s exact test.
bn is number of subjects with baseline score and at least one postbaseline score.
Abbreviations: FACT-B, Functional Assessment of Cancer Therapy–Breast; FACT-G, Functional Assessment of Cancer
Therapy–General; HER-2, human epidermal growth factor receptor 2; MID  minimum important difference.
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evidence of a deleterious effect on patients’ QOL [17].
When toxicities were accounted for, lapatinib combined
with capecitabine provided more quality-adjusted survival
than capecitabine monotherapy [18]. Although the mecha-
nismforthiseffectislikelyaresultofthebettertumorstatusof
patients in the combination arm, the opportunity to delay or
avoid the toxic effects of chemotherapy is desirable.
Results shown here demonstrate clinically meaningful
declines in QOL scores associated with tumor progression
in patients with HR
 HER-2
 MBC. These hypothesis-
generating analyses suggest that these declines may take
more than a few months to evolve. The exploratory analy-
ses show that patients who remain on treatment and expe-
rience delayed progression have stable QOL and that a
higher percentage will show meaningful improvements in
Figure 2. Adjusted mean change from baseline for FACT-B total scores, by progression status, HER-2
 population. Least
squares mean changes (95% confidence interval) from analysis of covariance, adjusted for baseline score.
Abbreviations:FACT-B,FunctionalAssessmentofCancerTherapy–Breast;HER-2,humanepidermalgrowthfactorreceptor
2; MID, minimum important difference.
Figure 3. Distribution of QOL response based on minimum important difference FACT-B change from baseline, by progression
status, HER-2
 population. Declined represents decrease from baseline of 7 points; improved is 7-point increase from base-
line. p-values are from Fisher’s exact test using patients with baseline and postbaseline QOL scores.
Abbreviations:FACT-B,FunctionalAssessmentofCancerTherapy–Breast;HER-2,humanepidermalgrowthfactorreceptor
2; QOL, quality of life.
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progresses. These findings are not particularly surprising,
but the QOL benefits of delayed progression have not been
previously demonstrated so clearly. Based on these find-
ings, we anticipate that the QOL decline associated with
progression is delayed when disease progression can be de-
layed for several months, as seen with combination lapa-
tinib and letrozole treatment. If future study designs
continue QOL assessments after disease progression, it
would be possible to more fully evaluate the true value of
treatments that delay or interrupt the disease process. A full
year of assessments would directly demonstrate the degree
towhichdelayedprogressiontranslatesintoaQOLbenefit.
Not only could we determine the timing of the QOL
changes for the patient, but we could also begin to answer
questions about whether lingering effects of treatment ac-
crue after treatment end. For example, does delay of tumor
progressionequatetoaslowerdeclineforthepatient?Anal-
ysisapproachessuchastimetoQOLdeclinewouldbemore
meaningfulbecausetheQOLmeasurewouldnothavetobe
censored precisely at progression. In the meantime, we rely
on QOL assessments during the treatment phase and at
study withdrawal to infer that patient QOL is served by
slowing tumor growth.
Our current understanding of the most aggressive form
of MBC suggests that combination treatment provides pos-
itive clinical results and interrupts signaling pathways that
could have a multiplicative effect on tumor growth. Be-
cause MBC is not curable, maintenance of QOL is an im-
portant goal. Treatment with an anti-HER-2 agent in
combination with endocrine therapy may help support this
goal while reserving chemotherapy for when the disease
stops responding to endocrine modulation. Furthermore,
thecombinationofantiendocrineandanti–HER-2therapies
may delay tumor endocrine resistance via cointerruption of
the ER and EGFR networks [19]. The National Compre-
hensive Cancer Network guidelines support the use of en-
docrine therapy and only recommend chemotherapy with
trastuzumabforpatientswithvisceralcrisis.Thus,effective
treatment of patients with HR
 HER-2
 tumors relies on
concurrent inhibition of the ER and HER-2 networks.
In summary, the addition of lapatinib to letrozole led to
a significantly longer PFS interval than with antiestrogen
therapy (letrozole) alone, whereas the average QOL was
unchanged for patients who remained on study, thus con-
firming the clinical benefit of the combination therapy in
the HR
 HER-2
 MBC patient population. This combina-
tion provides an effective option in this patient population
by maintaining QOL during treatment and delaying the
need for chemotherapy and its accompanying side effects.
As an all oral regimen, it also has the potential to offer ben-
efitstopatientsintermsofconvenienceandpreference,ata
stageintheirdiseaseinwhichtheirtimeandenergyislikely
to be limited.
ACKNOWLEDGMENTS
We thank the patients who participated in the study and
theirfamilies;themedical,nursing,andresearchstaffatthe
study centers; the independent data and safety monitoring
committee; and the monitors, clinical operations staff, data
managers, statisticians, and programmers at GlaxoSmith-
Kline. Preliminary results of analyses were presented as
posters at conferences [20–22]. The EGF30008 study and
the QOL analyses reported in this paper were funded by
GlaxoSmithKline. The study is registered in ClinicalTrials.
gov (NCT00073528).
AUTHOR CONTRIBUTIONS
Conception/Design: Beth Sherrill, Mayur M. Amonkar
Financial support: Mayur M. Amonkar
Provisionofstudymaterialorpatients:MayurM.Amonkar,JulieMaltzman,
Lisa O’Rourke, Stephen Johnston
Collection and/or assembly of data: Mayur M. Amonkar, Julie Maltzman,
Lisa O’Rourke
Data analysis and interpretation: Beth Sherrill, Bintu Sherif
Manuscript writing: Beth Sherrill, Mayur M. Amonkar, Bintu Sherif
Final approval of manuscript: Beth Sherrill, Mayur M. Amonkar, Julie
Maltzman, Lisa O’Rourke, Stephen Johnston
The authors take full responsibility for the content of the paper but thank Adele
Monroe (medical editor) and Candy Webster (graphic artist) at RTI Health
Solutions for their editorial and production assistance. Ms. Monroe provided
copyediting (e.g., grammatical and punctuation assistance) and editorial assis-
tance (e.g., preparing references, labeling tables). Ms. Webster is a graphic art-
ist who converted SAS-generated figures into JPG files (i.e. production
assistance, assembling tables, graphs, figures).
REFERENCES
1 Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin
2009;59:225–249.
2 ArpinoG,WeichmannL,OsborneCKetal.Crosstalkbetweentheestrogen
receptor and the HER tyrosine kinase receptor family: molecular mecha-
nismandclinicalimplicationsforendocrinetherapyresistance.EndocrRev
2008;29:217–233.
3 HurtadoA,HolmesKA,GeistlingerTRetal.RegulationofERBB2byoes-
trogenreceptor-PAX2determinesresponsetotamoxifen.Nature2008;456:
663–666.
4 Lipton A, Ali SM, Leitzel K et al. Serum HER-2/neu and response to the
aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 2003;21:
1967–1972.
5 Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J
Cancer 2001;37(suppl 4):S9–S15.
6 Yang Z, Barnes CJ, Kumar R. Human epidermal growth factor receptor 2
status modulates subcellular localization of and interaction with estrogen
receptor alpha in breast cancer cells. Clin Cancer Res 2004;10:3621–3628.
7 Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole
versus anastrozole alone for the treatment of postmenopausal women with
human epidermal growth factor receptor 2–positive, hormone receptor–
952 Quality of Life in MBC Patientspositive metastatic breast cancer: Results from the randomized phase III
TAnDEM study. J Clin Oncol 2009;27:5529–5537.
8 Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the
efficacy and safety of trastuzumab combined with docetaxel in patients
with human epidermal growth factor receptor 2-positive metastatic breast
canceradministeredasfirst-linetreatment:TheM77001studygroup.JClin
Oncol 2005;23:4265–4274.
9 Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a
monoclonal antibody against HER2 for metastatic breast cancer that over-
expresses HER2. N Engl J Med 2001;344:783–792.
10 Coleman RE. Skeletal complications of malignancy. Cancer 1997;80(8
suppl):1588–1594.
11 Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin On-
col 2004;22:3608–3617.
12 Lin NU, Winer EP. Brain metastases: The HER2 paradigm. Clin Cancer
Res 2007;13:1648–1655.
13 Mundy GR. Metastasis to bone: Causes, consequences and therapeutic op-
portunities. Nat Rev Cancer 2002;2:584–593.
14 Johnston S, Pippen J Jr, Pivot X et al. Lapatinib combined with letrozole
versus letrozole and placebo as first-line therapy for postmenopausal hor-
mone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:
5538–5546.
15 Brady MJ, Cella DF, Mo F et al. Reliability and validity of the Functional
Assessment of Cancer Therapy–Breast quality-of-life instrument. J Clin
Oncol 1997;15:974–986.
16 EtonDT,CellaD,YostKJetal.Acombinationofdistribution-andanchor-
based approaches determined minimally important differences (MIDs) for
fourendpointsinabreastcancerscale.JClinEpidemiol2004;57:898–910.
17 ZhouX,CellaD,CameronDetal.Lapatinibpluscapecitabineversuscape-
citabine alone for HER2 (ErbB2) metastatic breast cancer: Quality-of-
life assessment. Breast Cancer Res Treat 2009;117:577–589.
18 Sherrill B, Amonkar MM, Stein S et al. Q-TWiST analysis of lapatinib
combined with capecitabine for the treatment of metastatic breast cancer.
Br J Cancer 2008;99:711–715.
19 Xia W, Bacus S, Hegde P et al. A model of acquired autoresistance to a
potentErbB2tyrosinekinaseinhibitorandatherapeuticstrategytoprevent
its onset in breast cancer. Proc Natl Acad SciUSA2006;103:7795–7800.
20 SherrillB,AmonkarMM,SherifBNetal.Anexplorationoftheassociation
of quality-of-life (QOL) scores with tumor progression status in first line
hormone receptor positive, HER2 metastatic breast cancer (MBC) pa-
tients treated with lapatinib plus letrozole or letrozole alone (poster 5106).
PresentedattheSanAntonioBreastCancerSymposium,SanAntonio,TX,
December 9–13, 2009.
21 Sherrill B, Sherif BN, Amonkar MM et al. Quality-of-life and quality-
adjusted survival (Q-TWiST) in patients receiving lapatinib plus letrozole
asfirst-linetherapyinhormonereceptorpositive,HER2metastaticbreast
cancer (MBC). Oral presentation and poster presented at the American So-
ciety of Clinical Oncology Breast Cancer Symposium, San Francisco, CA,
October 8, 2009.
22 Sherif BN, Sherrill B, Amonkar M et al. Lapatinib plus letrozole compared
with letrozole alone as first-line therapy in hormone receptor positive
HER2metastaticbreastcancer:Aqualityoflifeanalysis.Presentedatthe
American Society of Clinical Oncology annual meeting, Orlando, FL, May
29 to June 2, 2009.
953 Sherrill, Amonkar, Sherif et al.
www.TheOncologist.com